Allogeneic stem cell transplantation (SCT) for the treatment of 15 patients with paroxysmal nocturnal hemoglobinuria (PNH) in Brazil  by Oliveira, M.M. et al.
2-9). Acute GvHD (grade I, at day 47 and day 97 [patient who
had prior allogeneic transplant with chronic GvHD]) was observed
in 2 patients while mild chronic GvHD in 7 (grade II, one due to
donor lymphocyte infusion). With a median follow-up of 13.5
months (9.5-20), 12 patients were alive and 9 remained in CR. No
transplant related mortality was seen but 2 AML patients had early
relapsed (day 59, and 130). Conclusion: The NMT regimen
with triple GVHD prophylaxis appears to be safe with no trans-
plant related mortality. It may be an effective treatment for hema-
tological malignancies in Asian patients with high risk features.
Longer follow-up and additional patients are required to conﬁrm
the efﬁcacy.
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SEQUENTIAL ADMINISTRATION OF SARGRAMOSTIM (GM-CSF) AND
FILGRASTIM (G-CSF) IN PEDIATRIC ALLOGENEIC STEM CELL TRANS-
PLANT (AlloSCT) RECIPIENTS UNDERGOING MYELOABLATIVE (MA)
CONDITIONING: COST-EFFECTIVE AND MORE RAPID PLATELET RE-
COVERY IN UCB RECIPIENTS
Militano, O.1, Boskoff, B.2, Del Toro, G.3, van deVen, C.3,
Satwani, P.3, Bradley, B.3, George, D.3, Garvin, J.H.3, Bhatia, M.3,
Roman, E.3, Wolownik, K.3, Foley, S.3, Hawks, R.3, Shwartz, J.4,
Cheung, K.5, Cairo, M.S.3,4,6 1. Department of Pharmacy, New York
Presbyterian Hospital, New York, NY; 2. Vanderbilt University, Nash-
ville, TN; 3. Department of Pediatrics, Columbia University, New York,
NY; 4. Department of Pathology, Columbia University, New York, NY;
5. Department of Biostatistics, Columbia University, New York, NY; 6.
Department of Medicine, Columbia University, New York, NY.
G-CSF or GM-CSF can hasten myeloid engraftment post MA
AlloSCT. GM-CSF is an earlier and broader acting CSF, which
also induces more TH1. DC1 immune subsets preferentially
compared to G-CSF. The objective of this study is to evaluate
efﬁcacy/safety of sequential administration of GM-CSF fol-
lowed by G-CSF in children s/p MA AlloSCT. From 1/01-6/05
we enrolled 34 children: mean age 7.2 yrs; wt 32.3 kg; M:F 
19:15; poor:average risk  13:21, TBI vs non-TBI based con-
ditioning  12:22; MFD vs umbilical cord blood (UCB) 
12:22. Indications for AlloSCT included malignant (MDS,
ALL, AML, APL, NHL [n  22]) and non-malignant (SAA,
HLH, SCD, B-thal [n  12]) disorders. GM-CSF (250 g/m2
IV QD) was initiated on day 0 post stem cell infusion. GM-CSF
was switched to G-CSF (10 g/kg IV QD) when WBC 300/
mm3  2 days. G-CSF was continued until ANC 2500/mm3 
2 days, then tapered to maintain ANC 1000/mm3. GVHD
prophylaxis: tacrolimus (target 5-20 ng/mL) and mycophenolate
as previously described (Osunkwo/Cairo, BBMT 2004). All pts
were prophylaxed against PCP, HSV, CMV, and fungal infec-
tions. There were no statistically signiﬁcant differences in base-
line characteristics between MFD vs UCB groups. Mean
CD34 cell dose/kg  36.3  105 and TNC dose/kg  39.3 
107. Median time to WBC 300/mm3  15.5 d (10 vs 19.5 d
MFD vs UCB). Median time of switch from GM-CSF (WBC
300/mm3) to G-CSF and myeloid engraftment (ANC 500/
mm3  2 d) was 0.5 d (1.5 vs 3.5 d MFD vs UCB). Median time
to myeloid and platelet engraftment (untransfused count
20000/mm3  7 d) were 17 d (13 vs 23.5 d MFD vs UCB) and
28 d (19 vs 33.5 d MFD vs UCB). Kaplan-Meier probability of
1 year OS was 67.2% (CI: 50.3-84.1). Adverse events attribut-
able to G-CSF (n  1) or GM-CSF (n  3) were: bone pain,
pleural and pericardial effusions. Of these, 3/4 pts received
concomitant oprelvekin (IL-11). Infections occurring prior to
day 60 included 21 (62%) pts with CVL bacteremia (coagulase
() staphylococci [n  9], gram () bacilli [n  10]) and 2 (6%)
pts with invasive fungal infections. This pilot study demon-
strated safety and efﬁcacy of sequential GM-CSF/G-CSF ad-
ministration in pediatric AlloSCT recipients. Myeloid recovery
after WBC 300/mm3 on GM-CSF only took 1-3 days after
switch to G-CSF. Platelet engraftment following UCBT ap-
pears more rapid with sequential GM-CSF/G-CSF compared to
historical controls. Sequential GM-CSF/G-CSF may be more
cost-effective than G-CSF alone (cost-saving of $1402/patient
based on 2004 Red Book AWP).
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR THE TREAT-
MENT OF 15 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLO-
BINURIA (PNH) IN BRAZIL
Oliveira, M.M., Bonﬁm, C., Bitencourt, M., Funke, V., Setubal, D.,
Ruiz, J., Medeiros, C.R., Zanis-Neto, J., Pasquini, R. Federal Univer-
sity of Parana, Curitiba, PR, Brazil.
PNH is a clonal disorder caused by acquired mutations of the
PIG-A gene. Many pts achieve long term survival if adverse
factors are not present. SCT can be curative for young pts with
severe pancytopenia, massive hemolysis, thrombotic complica-
tions or leukemic transformation. SCT complications are fre-
quent reported due to an increased risk of graft failure and
transplant related mortality. In this study we retrospectively
analyze 15 pts with PNH submitted to SCT in our BMT center.
Period: 03/88-02/05. Indication for SCT: severe pancytopenia:
12 pts, thrombosis: 2 pts and hemolysis: 1 pt. Age: 14-42 y (M:
29 y). Gender: 6F/9M. Time from diagnosis to SCT ranged
from 2 to 133 months (M: 29.5 mo). Previous blood transfu-
sions: 25 UI (range: 8-200 UI). Total nucleated cell infused:
1.72-4.56  108/kg (median: 2.7). Donor type: HLA identical
siblings: 14 pts, unrelated identical donor: 1 pt. Stem cell
source: bone marrow: 14 pts; peripheral blood: 1 pt. Preparatory
regimen: busulfan (BU) 12 mg/kg  cyclophosphamide (CY)
120 mg/kg: 11 pts (1 pt received BU 16 mg/kg), BU 8 mg/kg 
ﬂudarabine 125 mg/m2: 2 pts; CY 120 mg/kg  TBI ATG: 1
pt and CY 200 mg/kg: 1 pt. GVHD prophylaxis: methotrexate 
cyclosporine: 12 pts; others: 3 pts. Eleven pts are alive without
evidence of PNH with a median follow-up of 1691 days (range:
125-5998 days). Estimated 5 year survival: 73%. Two pts died
before day 28 and were not evaluable for engraftment. 13 pts
engrafted and the median time to reach ANC 	500/l was 19
days (range: 14-25). Mucositis grade III-IV occurred in 7 pts.
Two patients developed grade III-IV acute GVHD. One pt had
progressive extensive chronic GVHD and another one had de
novo extensive C-GVHD. No pt developed veno-occlusive dis-
ease. Four pts (median age of 36.5 yr) died on day 10, 11,
71 and 330 after SCT. Causes of death included infection (2
pts) and GVHD (2 pts).We conclude that pts with PNH and life
threatening complications can achieve long term survival after
SCT when HLA identical donors are used. In this group of
patents we did not observe signiﬁcant transplant related com-
plications.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
NON-HODGKIN’S LYMPHOMA IN QUEEN MARY HOSPITAL—A SINGLE
CENTRE EXPERIENCE
Lie, A.K.W., Leung, A.Y.H., Liang, R. Division of Hematology and
Bone Marrow Transplantation, The University of Hong Kong, Hong
Kong.
Objectives: Non-Hodgkin’s lymphoma (NHL) is one of the
major indications for haematopoietic stem cell transplantation
(HSCT). For chemo-sensitive relapsed cases, autologous HSCT is
often the treatment of choice. Relapsed cases after autologous
HSCT as well as those with extensive disease generally have poor
prognosis and allogeneic HSCT becomes the only option for a
cure. We summarized our experience in Queen Mary Hospital
regarding the outcome of allogeneic HSCT for this disease.Meth-
ods: Hospital records of allogeneic HSCT for underlying NHL in
the past fourteen years were retrieved. Clinical data were summa-
rized according to the pre-HSCT characteristics, disease relapse
and transplant-related mortality. Event-free (deﬁned as either dis-
ease relapse or death after HSCT) and overall survival were eval-
uated by Kaplan-Meier analysis. Results: Since 1991, a total of 48
NHL patients (M:F 25:23) have undergone allogeneic HSCT. The
median age was 42 (range: 23-63 years). Histological diagnoses
were obtained from 40 patients and they comprised both B-cell
(Burkitt or Burkitt-like  5, diffuse large B-cells  19, follicular 
3, maltoma  1, Mantle cell  3) or T-cell lymphoma (angioim-
munoblastic T-cell  3, T-lymphoblastic  4, peripheral T-cell 
2). Allogeneic HSCT was performed mostly as salvage therapy for
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